|
Market Closed -
Nasdaq
00:00:00 25/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 8.690 USD | -2.69% |
|
-6.05% | -17.24% |
| 03:30pm | Immatics Announces $150 Million Underwritten Offering | MT |
| 08-18 | Immatics' Q2 Net Loss Narrows as Revenue Rises | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.19B | - | ||||
| 69.06B | |||||
| 63.06B | |||||
| 28.34B | - | ||||
| 27.07B | - | ||||
| 25.45B |
- Stock Market
- Stocks
- IMTX Stock
- Charts Immatics N.V.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
